TITLE

2011 - Simvastatin plus ezetimibe reduced major atherosclerotic events in patients with chronic kidney disease

AUTHOR(S)
Laville, Maurice
PUB. DATE
November 2011
SOURCE
ACP Journal Club;11/15/2011, Vol. 155 Issue 5, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on a study which examined the effects of simvastatin plus ezetimibe in patients with chronic kidney disease. Information on the dosing regimen is provided. Results of the study showed that the simvastatin plus ezetimibe treatment regimen was effective than placebo in reducing the risk for major atherosclerotic events and major vascular events. The study did not found any difference for end-stage renal disease among study participants.
ACCESSION #
69859149

 

Related Articles

  • LDL control cuts CVD in CKD.  // Pulse;6/15/2011, Vol. 71 Issue 22, p4 

    The article reports on a study which discovered that lowering low-density lipoprotein (LDL) cholesterol with simvastatin plus ezetimibe safely reduces the risk of major atherosclerotic events in nearly all patients with chronic kidney disease (CKD) in Great Britain.

  • Effect of simvastatin plus ezetimibe on incidence of major atherosclerotic events in patients with advanced chronic kidney disease.  // Australian Journal of Pharmacy;Nov2011, Vol. 92 Issue 1098, p92 

    The article evaluates the efficacy and safety of a combination therapy (CT) of simvastatin and ezetimibe on the incidence of major atherosclerotic events (MAE) in patients with advanced chronic kidney disease (ACKD). A randomized, double blind trial was conducted on 9,270 ACKD patients with no...

  • FDA rejects new indication for use of combination ezetimibe plus simvastatin in patients with CKD.  // Cardiology Today;Mar2012, Vol. 15 Issue 3, p37 

    The article reports on the rejection by the U.S. Food and Drug Administration (FDA) of an indication for use of combination ezetimibe plus simvastatin to prevent major vascular events in patients with chronic kidney disease (CKD).

  • Landmark data from SHARP show substantial benefits from reducing cholesterol in patients with chronic kidney disease. Pinn, Stephen // British Journal of Hospital Medicine (17508460);Feb2011, Vol. 72 Issue 2, p71 

    The article presents findings from SHARP (Study of Heart and Renal Protection) trial which indicated that the cholesterol-lowering combination of cholesterol absorption inhibitor (ezetimibe) and HMG co-reductase inhibitor (simvastatin) significantly reduced major atherosclerotic events in...

  • SHARP: Ezetimibe plus statin reduced CV risk in patients with CKD.  // Endocrine Today;Dec2010, Vol. 8 Issue 12, p16 

    The article focuses on a study which revealed the effectiveness of long-term cholesterol-lowering treatment with ezetimibe plus simvastatin in reducing the risk for myocardial infarction, stroke and surgery to open blocked arteries among patients with chronic kidney disease, that was presented...

  • Should statins be prescribed for primary prevention of cardiovascular disease in patients with chronic kidney disease? Connor, Andrew; Tomson, Charlie // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/3/2009, Vol. 339 Issue 7724, p803 

    The article discusses whether statins should be prescribed for primary prevention of cardiovascular disease in patients having chronic kidney disease. The British National Institute for Health and Clinical Excellence (NICE) recommends treatment with statins for secondary prevention of...

  • Lipid Lowering Reduces CV Risk in CKD. SCHIESZER, JOHN // Renal & Urology News;Jan2011, Vol. 10 Issue 1, p15 

    The article reports on the findings of the Study of Heart and Renal Protection (SHARP) trial which aims to prevent cardiovascular (CV) events in patients with chronic kidney disease (CKD). It states that combination therapy of ezetimibe and simvastatin significantly reduces the risk of...

  • Quick Takes.  // Cortlandt Forum;Feb2008, Vol. 21 Issue 2, p19 

    The article offers news briefs in the U.S. A clinical study shows that the combination of ezetimibe/simvastatin (Vytorin) reduced plaque buildup compared with simvastatin (Zocor). Patients with chronic kidney disease who take one antihypertensive medication in the evening has declined in urinary...

  • Ezetimibe Therapy for Dyslipidemia: An Update. Katsiki, Niki; Theocharidou, Eleni; Karagiannis, Asterios; Athyros, Vasilios G.; Mikhailidis, Dimitri P. // Current Pharmaceutical Design;May2013, Vol. 19 Issue 15-17, p3107 

    Ezetimibe, an inhibitor of intestinal cholesterol absorption, can decrease total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglycerides (TGs) and apolipoprotein (apo) B levels and increase high-density lipoprotein cholesterol (HDL-C) levels. Apart from lipid-lowering,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics